Who is sponsoring NCT05122975?

NCT05122975 is sponsored by RyCarma Therapeutics, Inc..

What drugs are being tested in NCT05122975?

Interventions in NCT05122975: S48168 (ARM210), Matching Placebo.

What condition does NCT05122975 study?

NCT05122975 studies Catecholaminergic Polymorphic Ventricular Tachycardia Type 1.

Is NCT05122975 still recruiting?

NCT05122975 is currently terminated. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05122975

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of an Inherited Ventricular Arrhythmia

Terminated Phase 2 Last updated 19 September 2024

What this trial tests

Phase 2 trial testing S48168 (ARM210) in Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 in 8 participants. Terminated before completion.

Timeline

1 August 2023

Primary endpoint
1 April 2024

1 April 2024

Quick facts

Lead sponsor	RyCarma Therapeutics, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	8
Start date	1 August 2023
Primary completion	1 April 2024
Estimated completion	1 April 2024
Sites	2 locations across Netherlands, United States

Drugs / interventions tested

S48168 (ARM210) — full drug profile →
Matching Placebo — full drug profile →

Conditions studied

Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 — all drugs for Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 →

Sponsor

RyCarma Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Catecholaminergic Polymorphic Ventricular Tachycardia Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1). This disease is associated with fatal changes in heart rhythms leading to sudden death with exercise or excessive excitement. It is due to mutations in the Ryanodine Receptor calcium release channel, which cause leaky channels leading to the disease. S48168 (ARM210) repairs these leaky channels and can be a disease-modifying therapy restoring normal function to the channels. This result would allow patients with CPVT to live normal, active lives. Funding Source- FDA OOPD.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

RYR2-ryanodinopathies: from calcium overload to calcium deficiency.
Steinberg C, Roston TM, van der Werf C, Sanatani S, et al · · 2023 · cited 50× · PMID 37387319 · DOI 10.1093/europace/euad156
Application of next generation sequencing in cardiology: current and future precision medicine implications.
Papadopoulou E, Bouzarelou D, Tsaousis G, Papathanasiou A, et al · · 2023 · cited 6× · PMID 37424920 · DOI 10.3389/fcvm.2023.1202381
Targeting Calcium Regulation for Heart Failure and Arrhythmia Therapeutics: A Critical Review.
Redel-Traub G, Marx SO, Marks AR. · · 2025 · cited 1× · PMID 41021670 · DOI 10.1161/circulationaha.125.075150

Verify or expand the search:

Other recruiting trials for Catecholaminergic Polymorphic Ventricular Tachycardia Type 1

Currently open trials in the same condition.

NCT06661278 — Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias · recruiting

Other RyCarma Therapeutics, Inc. trials

Trials by the same sponsor.

NCT04141670 — S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05122975 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RyCarma Therapeutics, Inc.
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05122975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing